Table 1

 Current treatment recommendations for patients with chronic hepatitis C

HCV genotypeDuration (weeks)PEG-IFN dose (1×/week sc)Ribavirin dose (daily orally)
*Hepatitis C virus (HCV) genotypes 4–6 may respond better to pegylated IFN (PEG-IFN)/ribavirin than HCV genotype 1 patients. For HCV genotype 4, 36 weeks may be sufficient.109 Data are limited for HCV genotypes 5/6.
sc, subcutaneously.
Genotype 148180 μg PEG-IFN alpha-2a1000 mg (<75 kg)
Genotypes 4–6*1200 mg (⩾75 kg)
1.5 μg/kg PEG-IFN alpha-2b800 mg (<65 kg)
1000 mg (65–85 kg)
1200 mg (>85 kg)
Genotypes 2/324180 μg PEG-IFN alpha-2a800 mg (all)
1.5 μg/kg PEG-IFN alpha-2b800 mg (<65 kg)
1000 mg (65–85 kg)
1200 mg (>85 kg)